Therapeutic potentials of sarpogrelate in cardiovascular disease. - Wikidata - wikimedia - TriplyDB

Therapeutic potentials of sarpogrelate in cardiovascular disease.

Therapeutic potentials of sarpogrelate in cardiovascular disease.

http://www.wikidata.org/entity/Q35673144

about

Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice.Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans Blocking 5-HT2 receptor restores cardiovascular disorders in type 1 experimental diabetes.Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure.Effect of sarpogrelate on cardiovascular disorders The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Possible roles of 5-HT in vein graft failure due to intimal hyperplasia 5-HT, nitric oxide and vein graft.5-HT2A receptor antagonists inhibit hepatic stellate cell activation and facilitate apoptosis.Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study.A Novel Simultaneous Determination of Sarpogrelate and its Active Metabolite (M-1) in Human Plasma, Using Liquid Chromatography-Tandem Mass Spectrometry: Clinical Application Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study.Comprehensive Proteome Profiling of Platelet Identified a Protein Profile Predictive of Responses to An Antiplatelet Agent Sarpogrelate.A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.Sarpogrelate inhibits the expression of ICAM-1 and monocyte-endothelial adhesion induced by high glucose in human endothelial cells.Suppression of high lipid diet induced by atherosclerosis sarpogrelate.Strategies for the regulation of intracellular calcium in ischemic heart disease.Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.Critical role of TNF inhibition in combination therapy for elderly mice with atherosclerosis.Effect of food intake on the pharmacokinetics of sarpogrelate and its active metabolite following oral administration to beagle dogs.Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers.

P2860

Q28550517-CF53153E-A835-470E-869B-6943A6AEA73A Q28550589-E1DD122B-20C8-471F-919B-FD55FAA0087E Q35994934-8CFC2E58-9653-4E8C-99F9-6353350BA135 Q36523213-41663D8F-3180-4E5C-A11E-261E262F9B43 Q37265701-ECCEEB46-5291-4377-B5E1-52C550AD3296 Q37278065-F60E93BA-6207-4A5C-8BFA-33362E7BD0C4 Q37568760-DC098D1A-ECD1-4E38-8192-F2E9A76AB870 Q37953905-9800EF80-E8A5-484B-A78C-EE06DD49AC47 Q38053481-1D6FEB61-469C-41A3-875D-FC767F01A483 Q38093426-24823645-8739-4E50-83E3-9F84F6C69640 Q39202142-8C8F5F96-4ED7-4C6B-9ED9-DCEBAC149B47 Q39561933-C40A6646-D4E4-4E0A-A08D-29E83B182010 Q41200449-47278C20-38B6-485E-A14C-AB2889FB442D Q41352369-0752DD65-0826-49E3-B864-83142F8935E1 Q42687813-222EB094-4F10-4759-999D-346D376C9F22 Q42708993-99987F37-9BC7-493B-82BB-697CEB9A1351 Q42714592-C6F9B0B9-A839-4FC6-B08D-8900202E1174 Q42913768-C8C2F8D8-15FE-4F7A-B922-9A6D4BBB6A70 Q45168252-FB848A92-EBA0-4D0B-B6A5-2EDF1E661382 Q46408507-20FA4112-E37D-460A-A628-4292A5C08DF0 Q48038255-CE0005D3-EDC9-47E6-BC6C-94A3757592F0 Q51342608-BE9AB9F6-7454-4149-9495-FCB0DCF22635 Q53257546-753253A4-2A76-4FC0-A8A1-EEB3421AA7BC

P2860

Therapeutic potentials of sarpogrelate in cardiovascular disease.

http://www.wikidata.org/entity/Q35673144

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Therapeutic potentials of sarpogrelate in cardiovascular disease.

@ast

Therapeutic potentials of sarpogrelate in cardiovascular disease.

@en

type

label

Therapeutic potentials of sarpogrelate in cardiovascular disease.

@ast

Therapeutic potentials of sarpogrelate in cardiovascular disease.

@en

prefLabel

Therapeutic potentials of sarpogrelate in cardiovascular disease.

@ast

Therapeutic potentials of sarpogrelate in cardiovascular disease.

@en

P1433

Q35673144-3C74D561-D93B-4D88-A98A-8E56433C8C00

P1476

Q35673144-78B04A3C-759C-4B90-B39F-9761409C2920

P2093

Q35673144-175ADBB2-1E4D-4FF7-8D72-3D3C75CD3903

Q35673144-5CD30A98-CDA8-44B1-93C9-DB2A01D4CB03

Q35673144-818CD501-4172-4707-BFE0-C03E25D31D14

Q35673144-8642129E-DA9E-403B-946C-27FA3EE629DD

Q35673144-DA797E37-BDBD-4E04-AA1E-9BAC05726DC0

Q35673144-E38C3F25-B743-4E0C-B5A3-CAB014EAB6A1

P2860

Q35673144-04C0AD4E-4F3C-4A40-93CE-939434BB006B

Q35673144-0C0ECF19-7E44-4784-95A6-85E07B1CE8F5

Q35673144-233E332D-55DF-4EBE-90E5-3B237980ED5E

Q35673144-36A1E082-A573-4F32-A303-18E211A90E46

Q35673144-43C883FE-8D9B-4814-83AC-B11FA1A12390

Q35673144-76C05BA9-8444-4D30-B6F8-35EADA821704

Q35673144-CFF23813-47DB-406B-A314-6479A1B95B53

Q35673144-E55BDC3D-AFBD-4A05-9F82-4038D909EEC8

Q35673144-F30704EE-82C4-4AD4-8811-2A95314E907C

P304

Q35673144-03AF4F28-CD6C-4BE6-A042-B494E98D053E

P31

Q35673144-796C621D-62A9-4AEE-AEE3-B86A7E8B7FBD

P356

Q35673144-12D7FE6D-5B13-4AFA-A6CA-303763992978

P433

Q35673144-E2CE3167-2828-473F-9A55-A05625EF37C9

P478

Q35673144-D47B8CFE-1711-4E1B-AB43-B8F64876D8D1

P577

Q35673144-0306B4B7-892F-4DB2-A09A-8FCDAA58569B

P5875

Q35673144-D1420E73-0A12-4FFB-9357-150C520AF53D

P698

Q35673144-56A084D9-F000-4CC4-8477-7832508AF56A

P356

J.1527-3466.2004.TB00130.X

P1433

Cardiovascular Drug Reviews

P1476

Therapeutic potentials of sarpogrelate in cardiovascular disease.

@en

P2093

Amarjit S Arneja

http://www.w3.org/2001/XMLSchema#string

Harjot K Saini

http://www.w3.org/2001/XMLSchema#string

Hideo Kumamoto

http://www.w3.org/2001/XMLSchema#string

Naranjan S Dhalla

http://www.w3.org/2001/XMLSchema#string

Nobuakira Takeda

http://www.w3.org/2001/XMLSchema#string

Ramesh K Goyal

http://www.w3.org/2001/XMLSchema#string

P2860

Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist.

In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery.

Controlled trial of ketanserin in hypertension.

Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study.

Endothelium-derived relaxing factor and coronary vasospasm.

Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses.

Serotonin-induced coronary spasm in a swine model. A minor role of defective endothelium-derived relaxing factor.

MCI-9042: high affinity for serotonergic receptors as assessed by radioligand binding assay.

Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors.

P304

27-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1527-3466.2004.TB00130.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6126838

http://www.w3.org/2001/XMLSchema#string

P698

14978517

http://www.w3.org/2001/XMLSchema#string